China Pharma Holdings Operating Income 2012-2026 | CPHI
China Pharma Holdings operating income from 2012 to 2026. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
|
China Pharma Holdings Annual Operating Income (Millions of US $) |
|
|---|---|
| 2025 | $-3 |
| 2024 | $-5 |
| 2023 | $-3 |
| 2022 | $-4 |
| 2021 | $-3 |
| 2020 | $-3 |
| 2019 | $-20 |
| 2018 | $-10 |
| 2017 | $-19 |
| 2016 | $-8 |
| 2015 | $-14 |
| 2014 | $-39 |
| 2013 | $-19 |
| 2012 | $6 |
| 2011 | $22 |
|
China Pharma Holdings Quarterly Operating Income (Millions of US $) |
|
|---|---|
| 2026-03-31 | $-1 |
| 2025-12-31 | $-1 |
| 2025-09-30 | $-1 |
| 2025-06-30 | $-1 |
| 2025-03-31 | $-1 |
| 2024-12-31 | $-1 |
| 2024-09-30 | $-1 |
| 2024-06-30 | $-1 |
| 2024-03-31 | $-1 |
| 2023-12-31 | $-1 |
| 2023-09-30 | $-1 |
| 2023-06-30 | $0 |
| 2023-03-31 | $0 |
| 2022-12-31 | $-1 |
| 2022-09-30 | $-1 |
| 2022-06-30 | $-1 |
| 2022-03-31 | $-1 |
| 2021-12-31 | $-1 |
| 2021-09-30 | $-1 |
| 2021-06-30 | $-1 |
| 2021-03-31 | $-1 |
| 2020-12-31 | $-1 |
| 2020-09-30 | $-1 |
| 2020-06-30 | $0 |
| 2020-03-31 | $-1 |
| 2019-12-31 | $-19 |
| 2019-09-30 | $-1 |
| 2019-06-30 | $-1 |
| 2019-03-31 | $0 |
| 2018-12-31 | $-8 |
| 2018-09-30 | $-2 |
| 2018-06-30 | $-1 |
| 2018-03-31 | $0 |
| 2017-12-31 | $-14 |
| 2017-09-30 | $-2 |
| 2017-06-30 | $-2 |
| 2017-03-31 | $-1 |
| 2016-12-31 | $-3 |
| 2016-09-30 | $-2 |
| 2016-06-30 | $-2 |
| 2016-03-31 | $-1 |
| 2015-12-31 | $-15 |
| 2015-09-30 | $3 |
| 2015-06-30 | $1 |
| 2015-03-31 | $-4 |
| 2014-12-31 | $-22 |
| 2014-09-30 | $-6 |
| 2014-06-30 | $-9 |
| 2014-03-31 | $-2 |
| 2013-12-31 | $-8 |
| 2013-09-30 | $-3 |
| 2013-06-30 | $-5 |
| 2013-03-31 | $-3 |
| 2012-12-31 | $-1 |
| 2012-09-30 | $2 |
| 2012-06-30 | $2 |
| 2012-03-31 | $3 |
| 2011-12-31 | $5 |
| 2011-09-30 | $6 |
| 2011-06-30 | $6 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.026B | $0.004B |
| CHINA PHARMA HOLDINGS, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd. (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |